An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Completed · Phase 3

Conditions studied: Macular Degeneration, Maculopathy, Age-Related

In brief

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Key facts

Study ID

NCT00058994

Run by

Alcon Research

Starts

2003-03-01

Expected to finish

2006-11-01

Last updated by the study team

2012-11-29

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• South America — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.